Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1716 ARTÍCULOS , VIENDO DEL 526 AL 540

Formaldehyde-Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives

Zhao H, Huang X, Tong Z.

ChemMedChem. 2021 Nov 19;16(22):3376-3390. doi: 10.1002/cmdc.202100428. Epub 2021 Sep 8.

The Structure Biology of Tau and Clue for Aggregation Inhibitor Design

Wang D, Huang X, Yan L, Zhou L, Yan C, Wu J, Su Z, Huang Y.

Protein J. 2021 Oct;40(5):656-668. doi: 10.1007/s10930-021-10017-6. Epub 2021 Aug 17.

Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer's disease

Wang J, Huang L, Wei L, Chen W.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Jun 25;50(3):383-389. doi: 10.3724/zdxbyxb-2021-0184.

Associations between Certain Polymorphisms in Proinflammatory Cytokines and Predisposition of Alzheimer's Disease: A Meta-Analysis

Zhang Q, Yang K, Zhang Z, Zhang R.

Dement Geriatr Cogn Disord. 2021;50(3):224-230. doi: 10.1159/000508889. Epub 2021 Aug 17.

Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting Aβ cascade pathogenesis

Chuang Y, Van I, Zhao Y, Xu Y.

J Chem Neuroanat. 2021 Nov;117:102014. doi: 10.1016/j.jchemneu.2021.102014. Epub 2021 Aug 15.

Microbiota-gut-brain axis and Alzheimer's disease: Implications of the blood-brain barrier as an intervention target

Liu S, Gao J, Liu K, Zhang HL.

Mech Ageing Dev. 2021 Oct;199:111560. doi: 10.1016/j.mad.2021.111560. Epub 2021 Aug 16.

Masitinib for the treatment of Alzheimer's disease

Ettcheto M, Cano A, Sanchez-López E, Verdaguer E, Folch J, Auladell C, Camins A.

Neurodegener Dis Manag. 2021 Aug;11(4):263-276. doi: 10.2217/nmt-2021-0019. Epub 2021 Aug 20.

Senile plaque calcification of the lamina circumvoluta medullaris in Alzheimer's disease

Schober R, Hilbrich I, Jäger C, Holzer M.

Neuropathology. 2021 Oct;41(5):366-370. doi: 10.1111/neup.12742. Epub 2021 Aug 20.

Cognition and Neuropsychiatric Symptoms in Alzheimer Disease: A Century-Old Problem

Sanders AE.

Neurology. 2021 Sep 28;97(13):615-616. doi: 10.1212/WNL.0000000000012616. Epub 2021 Aug 20.

The beneficial effect of exercise against Alzheimer's disease may result from improved brain glucose metabolism

Zhao N, Xu B.

Neurosci Lett. 2021 Oct 15;763:136182. doi: 10.1016/j.neulet.2021.136182. Epub 2021 Aug 18.

The pleiotropic roles of autophagy in Alzheimer's disease: From pathophysiology to therapy

Festa BP, Barbosa AD, Rob M, Rubinsztein DC.

Curr Opin Pharmacol. 2021 Oct;60:149-157. doi: 10.1016/j.coph.2021.07.011. Epub 2021 Aug 19.

Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer's Disease Patients

Qureshi ZP, Thiel E, Nelson J, Khandker R.

J Alzheimers Dis. 2021;83(4):1679-1690. doi: 10.3233/JAD-210713.

On the Nomenclature of the Alzheimer's Disease Amyloid and Its Precursor1

Robakis NK.

J Alzheimers Dis. 2021;83(1):3-4. doi: 10.3233/JAD-215138.

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD

Vijverberg EGB, Axelsen TM, Bihlet AR, Henriksen K, Weber F, Fuchs K, Harrison JE, Kühn-Wache K, Alexandersen P, Prins ND, Scheltens P.

Alzheimers Res Ther. 2021 Aug 23;13(1):142. doi: 10.1186/s13195-021-00882-9.

Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer's disease brains

Barrera J, Song L, Gamache JE, Garrett ME, Safi A, Yun Y, Premasinghe I, Sprague D, Chipman D, Li J, Fradin H, Soldano K, Gordân R, Ashley-Koch AE, Crawford GE, Chiba-Falek O.

Mol Neurodegener. 2021 Aug 24;16(1):58. doi: 10.1186/s13024-021-00481-0.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias